AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04394598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g tid per day for 5weeks
Study NCT00683228 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
Study NCT01019161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: 100mg Lyophile, 5mL Diluent IV infusion
Study NCT01019161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C14 AZD1152
Description: radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
Study NCT02797834 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial fluid collection
Study NCT03586310 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ear-EEG
Description: soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
Study NCT00496769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
Study NCT00496769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Tablets, oral, 81-324 mg, once daily, up to 156 weeks
Study NCT01056692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC000459
Description: Capsules twice daily for 15 days
Study NCT01056692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules twice daily for 15 days
Study NCT00004862 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00004862 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Study NCT00004862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00004862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT04228484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study NCT04228484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP receptor antagonization
Description: GIP(3-30)NH2 infusion
Study NCT00125450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy with Forced Expiratory Technique
Description: Chest Physiotherapy with Forced Expiratory Technique
Study NCT00125450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngeal Aspiration
Description: Nasopharyngeal Aspiration
Study NCT01461642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management asthma plan indorsment.
Description: Subjects adherence to asthma self management plan will be monitored through web-based support.
Study NCT00116688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study NCT02074202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F- fluorocholine
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
Study NCT02074202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F- fluorodeoxyglucose
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
Study NCT01719549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: * Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~* Study drug: TKI258 capsule~* Dose: 500mg p.o. qd~* Every 3 weeks
Study NCT01775670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-the-shelf splint
Description: Subjects will use an off-the-shelf splint
Study NCT01775670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OT Splint
Description: Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
Study NCT02880267 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CGM
Description: Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
Study NCT04155047 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Glyocopyrrolate Inhalation Solution administered by Magnair
Description: glycopyrrolate Inhalation Solution 25mcg, single dose
Study NCT04155047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administered by Magnair
Description: Placebo Inhalation Solution
Study NCT04120571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Audiological Intervention Device (SleepAID)
Description: subtle sound stimulation in phase with the slow oscillations
Study NCT04120571 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham control
Description: no noise
Study NCT02689843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone compound + Spironolactone
Description: Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
Study NCT02689843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg three times daily
Study NCT02689843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg once daily
Study NCT04331678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator App
Description: Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment.
Study NCT01068275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar plexus catheter
Description: lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
Study NCT01068275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral nerve catheter
Description: femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
Study NCT01068275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-shot femoral block
Description: single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
Study NCT03727542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjustment of atrioventricular delay in DDD packers
Description: Atrioventricular delays are going to be adjusted as 60 milisecond shorter than the patients' native PR intervals in patients with already implanted permanent pacemakers.
Study NCT00045526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00045526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03804489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aids
Description: Decision aids in helping the infant family to decide whether the infant will or will not receive the oral rotavirus vaccine.
Study NCT01597609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine
Description: 10 mg, taken orally once per day for 12 weeks
Study NCT01597609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sibutramine placebo
Description: taken orally once per day for 12 weeks
Study NCT02964325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol platelets (MIR PLTs)
Description: The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
Study NCT02964325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference platelets (REF PLTs)
Description: The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
Study NCT00400725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex® Shampoo
Description: Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
Study NCT00400725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clobex® Vehicle Shampoo
Description: Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
Study NCT00697099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00697099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00697099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study NCT00697099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study NCT02880254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kurbo
Description: health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
Study NCT02880254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Health Coach
Description: weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
Study NCT02812186 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep to Moderate NMB
Description: Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade.
Study NCT02812186 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Moderate to Deep NMB
Description: Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB.
Study NCT02812186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium
Study NCT02169440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 25 mg
Study NCT02169440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIA 9-1067
Description: BIA 9-1067 25 mg
Study NCT02169440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin 25 mg
Study NCT00400725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex® Shampoo
Description: Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
Study NCT04199559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells pulsed with antigen
Description: peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
Study NCT02169440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin 25 mg
Study NCT02277483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAIS®
Description: 10 X 1,000 / twice a week
Study NCT03799614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMBand lower dose
Description: Light-weight portable device that delivers low dose vibration to the arm
Study NCT03799614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMBand higher dose
Description: Light-weight portable device that delivers higher dose vibration to the arm
Study NCT00972621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrax II
Description: Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
Study NCT00972621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viscoat
Description: Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
Study NCT02958046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole/Domperidone
Description: DUOLANS 30/30 mg SR tablet per oral, one tablet daily
Study NCT06329700 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Surgical removal of a part of the liver
Study NCT03264911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin or Placebo
Description: Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
Study NCT03264911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin or Placebo
Description: Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
Study NCT00913848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
Study NCT00913848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Study NCT02137889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
Study NCT04075994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Agent and heart rate and rhythm monitor
Description: Use of the Relational Agent and heart rate and rhythm monitor daily for 120 days.
Study NCT04075994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Use of the WebMD app and heart rate and rhythm monitor daily for 120 days.
Study NCT04073446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Patients eligible for SCS
Study NCT04391998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: oral tablet twice daily after meals
Study NCT04391998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 500 mg oral twice daily
Study NCT04391998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: 200 mg oral single dose
Study NCT03152097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially available Diindolylmethane
Description: Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
Study NCT03152097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Commercially available Diindolylmethane
Description: Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
Study NCT03152097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
Study NCT03152097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
Study NCT02942992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resistance exercise
Description: resistance exercise
Study NCT02063672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix DCB
Study NCT02063672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Uncoated Balloon Angioplasty Catheter
Description: PTA Catheter
Study NCT00945841 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: inactivated split influenza vaccine
Description: 1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
Study NCT00236002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70mgm once a week for one year
Study NCT02324686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vitamin K1
Description: Vitamin K1 400 mcg orally three times a week on dialysis days for four months
Study NCT01547715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine
Description: All subjects received a single dose of Meningococcal ACWY conjugate vaccine
Study NCT03353792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CL/AP system
Description: CL/AP system enabled insulin pump/CGM combination
Study NCT03353792 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: usual diabetic care
Description: usual diabetic care (insulin pump therapy) along with CGM recording
Study NCT01317147 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass (RYGBP)
Study NCT00372138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP + autologous thrombin
Description: simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
Study NCT03056521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative information about pain
Description: It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
Study NCT00481884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RadiaPlexRx Gel
Description: RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
Study NCT00481884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquaphor Gel
Description: Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
Study NCT00735709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated immediate-release vortioxetine tablets
Study NCT00735709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study NCT01165307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills
Description: Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
Study NCT01165307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium pills
Description: As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
Study NCT04306016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory stimulation
Description: Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
Study NCT03025035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
Study NCT03025035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib administered orally twice a day